BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

BiPar Sciences, Inc. 

1000 Marina Boulevard
Suite 550
Brisbane  California  94005  U.S.A.
Phone: 650-635-6050 Fax: 650-635-6057


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Start Up





 Company News
Positive Phase II Results with Sanofi-Aventis (France) (SASY.PA) and BiPar Sciences, Inc.'s Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 1/6/2011 7:42:36 AM    More...
New Executive Leadership and CEO Announced for BiPar Sciences, Inc. 12/11/2009 7:56:59 AM    More...
BiPar Sciences, Inc. Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs 9/10/2009 8:59:39 AM    More...
US Oncology, Inc. (USON): US Oncology Research Network Participates in Phase III Follow-up Study To US Oncology, Inc. (USON)'s Investigational Cancer Drug BSI-201 7/23/2009 2:03:50 PM    More...
US Oncology, Inc. (USON) Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 Phase II of the Trial was Presented in 2009 BiPar Sciences, Inc. Plenary Session 7/20/2009 9:02:50 AM    More...
Sanofi-Aventis (France) (SASY.PA) and BiPar Sciences, Inc. Release: BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer 7/17/2009 8:44:45 AM    More...
New BiPar Sciences, Inc. Drug Class Promising in Breast Cancer 6/1/2009 7:13:50 AM    More...
BiPar Sciences, Inc.' Investigational PARP Inhibitor, BSI-201, to be Highlighted During American Society of Clinical Oncology's Plenary Session 5/18/2009 11:56:41 AM    More...
Sanofi-Aventis (France) (SASY.PA) Buys U.S. Cancer Firm, BiPar Sciences, Inc. for up to $500 Million 4/15/2009 7:09:49 AM    More...
BiPar Sciences, Inc. to Present At the 11th Annual BIO CEO & Investor Conference in New York City 2/3/2009 8:22:34 AM    More...
1234